LINZESS (linaclotide)

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a mission-driven, publicly traded biotech dedicated to advancing the treatment of gastrointestinal diseases and redefining the standard of care. Its cornerstone achievement is the discovery, development, and commercialization of the first-in-class GC-C agonist LINZESS® (linaclotide), a blockbuster therapy for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company's strategy centers on leveraging its proprietary GI platforms, commercial infrastructure, and deep scientific expertise to build a pipeline targeting organic GI diseases with high unmet need, including the late-stage development of apraglutide for short bowel syndrome.

Therapeutic Areas